Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc., received final approval from the FDA for its application to manufacture and market a generic version of Pfizer’s Xanax XR (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The company intends to launch this product immediately.

The company’s Alprazolam Extended-Release tablets will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.